Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Eur J Clin Microbiol Infect Dis ; 36(11): 2085-2092, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28647858

RESUMO

Determinants of persistent low-level viraemia [PLLV, a viral load (VL) of between 50 and 500 copies/mL] have not been elucidated. In a case-control study, we evaluated the influence of micronutrients on PLLV in a population of 454 HIV-1 adults having initiated antiretroviral therapy (ART) between January 2007 and December 2011. Plasma levels of retinol (vitamin A), 25-OH vitamin D2 + D3, vitamin E and zinc were measured at ART initiation in cases (PLLV after 6 months of ART) and in controls (VL <50 copies/mL after 6 months). Cases and controls were matched for the CD4 cell count (±50/mm3) and ethnic origin. Intergroup differences in demographic, biological and treatment parameters and sunshine intensity at ART initiation were adjusted using a propensity score. A receiver operating characteristic (ROC) curve was used to assess intergroup differences in plasma micronutrient levels. Thirty-three of the 454 patients (7.3%) displayed PLLV (median VL: 92 copies/mL). Patients were predominantly male (89%), Caucasian (64%) and CDC stage C (25%). The median age was 38 years, the median initial VL was 5.2 log10 copies/mL and the median CD4 count was 74/mm3. The 22 cases and matched controls were balanced in these respects, and had similar vitamin A/E levels. Two cases (9%) and 9 controls (41%) had a vitamin D level <10.3 ng/mL (p = 0.0015), and 2 cases (9%) and 10 controls (48%) had a zinc level <74.6 µg/dL (p = 0.04). Our results support in vitro studies suggesting that vitamin D favours HIV-1 replication and that HIV-1 is zinc-dependent. Wide-scale, prospective studies are required.


Assuntos
HIV-1/metabolismo , Micronutrientes/sangue , Vitamina D/sangue , Zinco/sangue , Adulto , Fármacos Anti-HIV/uso terapêutico , Contagem de Linfócito CD4 , Estudos de Casos e Controles , Feminino , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , HIV-1/efeitos dos fármacos , Humanos , Masculino , Curva ROC , Viremia/virologia , Vitamina A/sangue , Vitamina E/sangue , Zinco/metabolismo
2.
HIV Med ; 16(4): 219-29, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25522796

RESUMO

OBJECTIVES: The aim of the study was to identify factors associated with the time between opportunistic disease (OD) diagnosis and antiretroviral therapy (ART) initiation in HIV-infected patients presenting for care with an OD, and to evaluate the outcomes associated with any delay. METHODS: A multicentre cohort study was undertaken in London, Paris and Lille/Tourcoing. The medical records of patients diagnosed from 2002 to 2012 were reviewed. RESULTS: A total of 437 patients were enrolled in the study: 70% were male, the median age was 40 years, 42% were from sub-Saharan Africa, 68% were heterosexual, the median CD4 count was 40 cells/µL, and the most common ODs were Pneumocystis pneumonia (37%), tuberculosis (24%), toxoplasmosis (12%) and Kaposi's sarcoma (11%). Of these patients, 400 (92%) started ART within 24 weeks after HIV diagnosis, with a median time from OD diagnosis to ART initiation of 30 [interquartile range (IQR) 16-58] days. Patients diagnosed between 2009 and 2012 had a shorter time to ART initiation than those diagnosed in earlier years [hazard ratio (HR) 2.07; 95% confidence interval (CI) 1.58-2.72]. Factors associated with a longer time to ART initiation were a CD4 count ≥ 200 cells/µL (HR 0.30; 95% CI 0.20-0.44), tuberculosis (HR 0.40; 95% CI 0.30-0.55) and diagnosis in London (HR 0.62; 95% CI 0.48-0.80). Patients initiating 'deferred' ART (by ≥ 30 days) exhibited no difference in disease progression or immunovirological response compared with patients who had shorter times to ART initiation. Patients in the 'deferred' group were less likely to have ART modifications (HR 0.69; 95% CI 0.48-1.00) and had shorter in-patient stays (mean 14.2 days shorter; 95% CI 8.9-19.5 days) than patients in the group whose ART was not deferred. CONCLUSIONS: The time between OD diagnosis and ART initiation remains heterogeneous and relatively long, particularly in individuals with a high CD4 count or tuberculosis or those diagnosed in London. Deferring ART was associated with fewer ART modifications and shorter in-patient stays.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/imunologia , Fármacos Anti-HIV/administração & dosagem , Infecções por HIV/imunologia , Sarcoma de Kaposi/imunologia , Tuberculose/imunologia , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Infecções Oportunistas Relacionadas com a AIDS/fisiopatologia , Adulto , População Negra , Contagem de Linfócito CD4 , Estudos de Coortes , Progressão da Doença , Esquema de Medicação , Inglaterra/epidemiologia , Feminino , França/epidemiologia , Infecções por HIV/tratamento farmacológico , Infecções por HIV/fisiopatologia , Humanos , Masculino , Sarcoma de Kaposi/epidemiologia , Sarcoma de Kaposi/fisiopatologia , Fatores de Tempo , Tuberculose/epidemiologia , Tuberculose/fisiopatologia , População Branca
3.
J Hosp Infect ; 87(3): 179-81, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24954916

RESUMO

In non-endemic areas, malaria is mainly an imported disease. This article reports a case of transfusion-related Plasmodium falciparum malaria in a non-endemic area. Despite initial clinical signs consistent with malaria, the diagnosis was not elicited because of the absence of any identified epidemiological risk factors. The case indicates that transfusion-transmitted malaria still occurs in non-endemic countries. The role of laboratory testing to prevent and diagnose transfusion-transmitted malaria in non-endemic malaria countries is crucial.


Assuntos
Artroplastia de Quadril/efeitos adversos , Malária Falciparum/diagnóstico , Malária Falciparum/patologia , Plasmodium falciparum/isolamento & purificação , Reação Transfusional , Idoso , Feminino , Humanos
4.
Med Mal Infect ; 44(5): 229-31, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24840286

RESUMO

OBJECTIVE: We had for aim to describe the identification and management of a 14-clonal carbapenem-resistant Acinetobacter baumannii (CRAB) outbreak, following admission of a known CRAB-infected patient in an ICU. METHODS: We reviewed the carriers' files and outbreak management procedures. RESULTS: The index patient was admitted with strict isolation precautions. The outbreak started 2 months after his discharge. It persisted despite reinforcement of strict isolation precautions, staff and patient cohorting, and extensive environmental decontamination including 2 rounds of routine terminal cleaning and disinfection or 1 round of cleaning and disinfection followed by hydrogen peroxide treatment. A second epidemic peak, after 4 weeks without any case, led to another wide environmental sampling and decontamination rounds. The source of the CRAB outbreak was suspected to be the blood pressure cuffs Velcro. Switching to cuffs submersible in a disinfectant stopped the outbreak. CONCLUSIONS: CRAB outbreaks are difficult to manage and sources of persistent colonization can be unexpected.


Assuntos
Infecções por Acinetobacter/microbiologia , Acinetobacter baumannii/efeitos dos fármacos , Antibacterianos/farmacologia , Carbapenêmicos/farmacologia , Infecção Hospitalar/microbiologia , Descontaminação/métodos , Surtos de Doenças , Unidades de Terapia Intensiva , Esfigmomanômetros/microbiologia , Infecções por Acinetobacter/tratamento farmacológico , Infecções por Acinetobacter/epidemiologia , Infecções por Acinetobacter/prevenção & controle , Acinetobacter baumannii/isolamento & purificação , Adulto , Canal Anal/microbiologia , Antibacterianos/uso terapêutico , Carbapenêmicos/uso terapêutico , Portador Sadio/microbiologia , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/prevenção & controle , Desinfetantes , Desinfecção , Resistência Microbiana a Medicamentos , Contaminação de Equipamentos , Equipamentos e Provisões Hospitalares , França/epidemiologia , Hospitais Gerais , Humanos , Peróxido de Hidrogênio , Masculino , Isolamento de Pacientes , Quartos de Pacientes , Recursos Humanos em Hospital , Faringe/microbiologia , Precauções Universais
5.
Ann Dermatol Venereol ; 140(10): 619-22, 2013 Oct.
Artigo em Francês | MEDLINE | ID: mdl-24090892

RESUMO

BACKGROUND: Syphilis has been making a comeback over the last 10 years. Neurosyphilis can occur at any stage of the infection but is difficult to diagnose because of the existence of misleading forms, of which we describe an example below. PATIENTS AND METHODS: A 56-year-old woman presented symptoms evoking polymyalgia rheumatica and giant-cell arteritis in a context of ibuprofen treatment for a few weeks. She also had myodesospsia, syphilids and syphilitic roseola, together with laboratory indicators of inflammation. A lumbar puncture revealed lymphocytic meningitis and a positive Treponema Pallidum Haemagglutination Assay (TPHA) for cerebrospinal fluid, thus confirming the diagnosis of neurosyphilis. Moreover, the ophthalmologic examination showed optic neuritis with papilla lesions of syphilitic origin. This was successfully treated with a 3-week course of penicillin G infusions. CONCLUSION: Symptoms evocative of Horton's disease and polymyalgia rheumatica can reveal syphilis, a disease dubbed "the great simulator" on account of the variety of clinical forms it can take.


Assuntos
Arterite de Células Gigantes/diagnóstico , Neurossífilis/diagnóstico , Polimialgia Reumática/diagnóstico , Astenia/etiologia , Biópsia , Diagnóstico Diferencial , Feminino , Testes de Hemaglutinação , Humanos , Pessoa de Meia-Idade , Morbidade/tendências , Neurossífilis/líquido cefalorraquidiano , Neurossífilis/complicações , Neurossífilis/tratamento farmacológico , Neurossífilis/microbiologia , Neurite Óptica/etiologia , Penicilina G/uso terapêutico , Sífilis/diagnóstico , Sífilis/epidemiologia , Artérias Temporais/patologia , Treponema pallidum/isolamento & purificação
6.
Med Mal Infect ; 41(9): 489-92, 2011 Sep.
Artigo em Francês | MEDLINE | ID: mdl-21840146

Assuntos
Infecções Oportunistas Relacionadas com a AIDS/complicações , Abscesso/etiologia , HIV-1 , Síndrome Inflamatória da Reconstituição Imune/etiologia , Linfadenite/etiologia , Infecção por Mycobacterium avium-intracellulare/complicações , Abscesso/cirurgia , Adulto , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/uso terapêutico , Terapia Antirretroviral de Alta Atividade , Antituberculosos/uso terapêutico , Axila , Claritromicina/administração & dosagem , Claritromicina/uso terapêutico , Darunavir , Didesoxinucleosídeos/administração & dosagem , Didesoxinucleosídeos/uso terapêutico , Enfuvirtida , Etambutol/administração & dosagem , Etambutol/uso terapêutico , Proteína gp41 do Envelope de HIV/administração & dosagem , Proteína gp41 do Envelope de HIV/uso terapêutico , Humanos , Isoniazida/administração & dosagem , Isoniazida/uso terapêutico , Lamivudina/administração & dosagem , Lamivudina/uso terapêutico , Excisão de Linfonodo , Linfadenite/cirurgia , Masculino , Infecção por Mycobacterium avium-intracellulare/cirurgia , Fragmentos de Peptídeos/administração & dosagem , Fragmentos de Peptídeos/uso terapêutico , Pirazinamida/administração & dosagem , Pirazinamida/uso terapêutico , Rifampina/administração & dosagem , Rifampina/uso terapêutico , Ritonavir/administração & dosagem , Ritonavir/uso terapêutico , Estreptomicina/administração & dosagem , Estreptomicina/uso terapêutico , Sulfonamidas/administração & dosagem , Sulfonamidas/uso terapêutico
7.
Infection ; 39(5): 473-6, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21830134

RESUMO

OBJECTIVES: To evaluate the role of Staphylococcus simulans in bone and joint infections (BJI) and determine their main characteristics. METHODS: A search of the database of the microbiology laboratories of Lille hospital and Tourcoing hospital was performed. Only results from blood, bone, and orthopedic device cultures were taken into account for hospitalized patients between January 2004 and January 2009. We considered cases in which S. simulans was the only bacteria isolated in all of the patients' biological samples with clinical and laboratory signs of infection. For patients with complete medical records, we recorded the clinical and epidemiological data. RESULTS: Six cases of BJI due to S. simulans were recorded, with five cases related to orthopedic devices infections. Three patients lived in rural areas. In four out of six patients, S. simulans was isolated in intraoperative biopsy material. In one patient, S. simulans grew in synovial fluid and in another in blood cultures only. The latter patient had a spondylodiscitis, and chronic foot ulcers due to gout disease were suspected to be the origin of the infection. All patients were healed after a mean follow up of 9 ± 3 months. Orthopedic devices were removed in four of the five patients concerned. The combination of rifampicin plus levofloxacin was used in four patients. CONCLUSION: The present data suggest that, even though S. simulans remains rarely observed in clinical pathology, its role in osteoarticular infections, especially in the case of infected orthopedic devices, is not exceptional. As for the antibiotic treatment, the combination of rifampicin and levofloxacin seems to be an effective strategy according to our clinical results.


Assuntos
Antibacterianos/uso terapêutico , Dispositivos de Fixação Ortopédica/efeitos adversos , Infecções Relacionadas à Prótese/tratamento farmacológico , Infecções Estafilocócicas/tratamento farmacológico , Staphylococcus/isolamento & purificação , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , França , Humanos , Dispositivos de Fixação Ortopédica/microbiologia , Infecções Relacionadas à Prótese/microbiologia , Infecções Estafilocócicas/microbiologia , Staphylococcus/efeitos dos fármacos , Resultado do Tratamento
9.
Int J Tuberc Lung Dis ; 14(4): 471-81, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20202306

RESUMO

OBJECTIVE: To evaluate the cost-effectiveness of the tuberculin skin test (TST), the QuantiFERON-TB Gold test (QFT) and a combination of TST and QFT (TST+QFT) for diagnosing latent tuberculosis infection (LTBI) in France in a bacille Calmette-Guérin (BCG) vaccinated population. METHODS: A decision analysis model evaluated three strategies among simulated adults in close contact with tuberculosis (TB). We calculated direct lifetime medical costs, life expectancies and incremental cost-effectiveness ratios (ICERs). RESULTS: The discounted direct medical costs of care per patient of no testing, TST, QFT and TST+QFT were respectively euro417, euro476, euro443 and euro435, while discounted life expectancies were respectively 25.030, 25.071, 25.073 and 25.062 years. TST had higher costs and lower efficacy than QFT; TST+QFT was associated with an ICER of euro560 per year of life gained (YLG) compared to no testing, and QFT was associated with an ICER of euro730/YLG compared to TST+QFT. The only scenario where QFT was associated with an ICER of >euro75 000/YLG was when the prevalence of LTBI around TB was low (<5%) and TST specificity high (>90%). CONCLUSIONS: In France, for the diagnosis of LTBI after close contact with TB, the TST is more expensive and less effective than QFT. Although it is more expensive, QFT is more effective and cost-effective than TST+QFT under a wide range of realistic test performance scenarios.


Assuntos
Vacina BCG , Custos de Cuidados de Saúde , Interferon gama/análise , Tuberculose Latente/diagnóstico , Tuberculose Latente/economia , Programas de Rastreamento/economia , Kit de Reagentes para Diagnóstico/economia , Teste Tuberculínico/economia , Adulto , Simulação por Computador , Busca de Comunicante , Análise Custo-Benefício , Técnicas de Apoio para a Decisão , Árvores de Decisões , França , Humanos , Tuberculose Latente/imunologia , Expectativa de Vida , Programas de Rastreamento/métodos , Valor Preditivo dos Testes
10.
Ann Dermatol Venereol ; 135(6-7): 451-8, 2008.
Artigo em Francês | MEDLINE | ID: mdl-18598794

RESUMO

BACKGROUND: The usual presentation of secondary syphilis is with cutaneous and mucosal symptoms. However, systematic symptoms can also occur. The purpose of this study was to describe non-mucocutaneous manifestations of secondary syphilis. PATIENTS AND METHODS: Patients from the Infectious Diseases Department of Tourcoing Hospital in whom secondary syphilis was diagnosed between January 2000 and December 2006 were enrolled in this study. Patients with secondary syphilis had the typical cutaneous and mucosal symptoms and a VDRLgreater than or equal to one quarter (or a fourfold increase in the VDRL if previously positive). RESULTS: Seventy-seven patients presenting a total of 80 cases of secondary syphilis were enrolled, 50 of whom were HIV-positive. Of these patients, 21 (26.3 p. 100) had neurological symptoms with three cases (3.8 p. 100) of uveitis, four (5 p. 100) of papillitis, two (2.5 p. 100) of retinitis and one (1.25 p. 100) of otosyphilis. In 14 of these 21 patients (67 p. 100), lumbar puncture was performed, confirming the diagnosis of neurosyphilis in six cases. Three patients (3.8 p. 100) had diarrhoea, four (5 p. 100) had abdominal pain and six (7.5 p. 100) had hepatomegaly. Seven (11.5 p. 100) patients had alanine aminotransferase levels above twice the normal upper limit and two above 10 times the normal upper limit. Three patients had bone pain and in one patient, osteitis was confirmed by technetium and gallium scintigraphy (osteolysis). CONCLUSION: In patients with secondary syphilis, clinicians should search for non-mucocutaneous symptoms. In the presence of these symptoms, appropriate syphilis treatment should be initiated.


Assuntos
Sífilis/complicações , Sífilis/diagnóstico , Adolescente , Adulto , Fatores Etários , Idoso , Cardiolipinas , Colesterol , Estudos de Coortes , Interpretação Estatística de Dados , Oftalmopatias/diagnóstico , Oftalmopatias/etiologia , Feminino , França/epidemiologia , Infecções por HIV/complicações , Infecções por HIV/diagnóstico , Soropositividade para HIV , Hepatomegalia/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Neurossífilis/diagnóstico , Osteíte/diagnóstico , Osteíte/etiologia , Otorrinolaringopatias/diagnóstico , Otorrinolaringopatias/etiologia , Fosfatidilcolinas , Estudos Prospectivos , Estudos Retrospectivos , Fatores Sexuais , Fatores Socioeconômicos , Punção Espinal , Sífilis/epidemiologia , Sorodiagnóstico da Sífilis/métodos
11.
HIV Clin Trials ; 9(3): 192-201, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18547906

RESUMO

OBJECTIVE: To assess the effect of the multidrug resistance-1 single nucleotide polymorphism (ABCB1 SNP) C3435T in exon 26 on the virological responses to first-line protease inhibitor (PI)-containing HAART regimens. METHOD: A cohort of 182 HIV-infected patients with a PI-containing HAART regimen initiated from 1997 to 2004 was enrolled. Time to the first indetectable viral load (VL) was determined in patients with the CC, CT, or TT genotype. RESULTS: There were 37%, 44%, and 19% of patients who had the CC, CT and TT genotypes, respectively. The median estimated times to VL indetectability in the CC, CT, and TT groups were respectively 5.9, 3.9, and 4.8 months (p= .06). In patients on a non-boosted PI regimen, ABCB1 genotype was associated with time to VL indetectability that was shorter in patients with the CT than CC genotype (CT vs. CC, hazard ratio [HR]=0.62, p= .02; TT vs. CC, HR= 0.72, p= .21). This association was not found in patients with first-generation boosted PI-containing regimens and especially not with second-generation boosted PI-containing regimens. CONCLUSION: Our results show that the ABCB1 SNP in exon 26 is associated with virological efficacy in HIV-infected patients treated with non-boosted PI-containing regimens but not with those containing boosted PIs, particularly of the second generation.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Terapia Antirretroviral de Alta Atividade , Infecções por HIV/tratamento farmacológico , Infecções por HIV/genética , Inibidores da Protease de HIV/uso terapêutico , Polimorfismo de Nucleotídeo Único , Subfamília B de Transportador de Cassetes de Ligação de ATP , Adulto , Feminino , Predisposição Genética para Doença , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
12.
Vaccine ; 26(5): 706-15, 2008 Jan 30.
Artigo em Inglês | MEDLINE | ID: mdl-18166250

RESUMO

OBJECTIVES: To assess the effectiveness and cost-effectiveness of routine childhood vaccination by new vaccines against rotavirus in France. METHODS: We constructed a Markov decision tree to compare two alternatives: "no vaccination" and "vaccination". A hypothetical birth cohort of 750,000 children was followed until 3 years of age. First, the disease burden without vaccine was estimated using data from French databases and medical literature. Incidence rates in unvaccinated children were modelled as a function of age and seasons. Next, using data from the medical literature, the vaccine's protective effect on rotavirus diarrhoea was considered. RESULTS: A routine universal rotavirus immunization programme was estimated capable of annually avoiding 89,000 cases of diarrhoea, 10,500 hospitalizations, and 8 deaths. At a vaccination cost of euro 150/course, assuming 75% vaccine coverage, the programme would cost euro 95 million and involve a net loss of euro 68 million to the health care system. The vaccination programme would cost euro 298,000/year of life saved, and euro 138,000/QALY saved. Key variables affecting the results were disease incidence, mortality rates and vaccine price. CONCLUSION: In France, childhood rotavirus vaccination with new anti-rotavirus vaccines would reduce the morbidity burden of rotavirus infection, but would not be cost-effective unless the price of vaccine decreased considerably.


Assuntos
Infecções por Rotavirus/economia , Infecções por Rotavirus/imunologia , Vacinas contra Rotavirus/economia , Rotavirus , Vacinação , Criança , Pré-Escolar , Comércio , Análise Custo-Benefício , França/epidemiologia , Custos de Cuidados de Saúde , Humanos , Programas de Imunização/economia , Lactente , Cadeias de Markov , Modelos Teóricos , Infecções por Rotavirus/prevenção & controle
13.
Med Mal Infect ; 37(6): 354-6, 2007 Jun.
Artigo em Francês | MEDLINE | ID: mdl-17303362

RESUMO

Pneumonia with septicemia caused by Pasteurella multocida was diagnosed in an immunocompetent patient exposed to a dog. This case is remarkable by two aspects: first the absence of visible cutaneous lesion, and second the localization and severity of the infection caused by P. multocida even though the patient was immunocompetent. P. multocida can cause respiratory and systemic infection, and it is a possible diagnosis in case of exposure to animals, even without history of bite or scratch. Furthermore, severe infections caused by this pathogen can occur in immunocompetent patients, so that the implication of specific host factors in the severity of the disease can be suspected. Genetic features could be one of these.


Assuntos
Cães/microbiologia , Infecções por Pasteurella/complicações , Pasteurella multocida , Sepse/microbiologia , Animais , Humanos , Imunocompetência , Masculino
14.
Vaccine ; 25(2): 298-305, 2007 Jan 04.
Artigo em Inglês | MEDLINE | ID: mdl-17055130

RESUMO

Rotavirus diarrhoea is associated with high childhood mortality in developing countries. A new vaccine was recently licensed in Mexico. The objective of this study was to assess the effectiveness of routine childhood vaccination by this new vaccine in a developing country. We constructed a decision tree to compare two alternatives: "no vaccination programme" and "vaccination programme". The estimates used for disease incidence, vaccine efficacy and coverage rates were derived from published data. We followed a hypothetical Nigerian cohort from birth to age five. The vaccine programme would prevent 284,000 cases of rotavirus diarrhoea annually and 6129 deaths due to the disease. In this study in a sub-Saharan country, we showed that rotavirus vaccination with a new vaccine substantially reduces the number of deaths from rotavirus diarrhoea and may be of great use in developing countries.


Assuntos
Vacinas contra Rotavirus/imunologia , Pré-Escolar , Humanos , Lactente , Recém-Nascido , Nigéria , Vacinação
15.
Rev Neurol (Paris) ; 162(1): 62-70, 2006 Jan.
Artigo em Francês | MEDLINE | ID: mdl-16446624

RESUMO

The tremendous progress achieved during the last few years with the use of highly active antiretroviral therapy in suppressing HIV replication together with improvements in immunity have been tempered by a growing number of new adverse effects. Mitochondrial toxicity is one aspect of these long-term toxicities of antiretroviral drugs, with the role of nucleoside analogs particularly underlined. Some cases of impaired mitochondrial function have been clearly identified, such as pancreatitis due to didanosine, neuropathy due to zalcitabine, myopathy due to zidovudine, and lactic acidosis due to stavudine. These mitochondrial toxicities can affect several organs, presenting different patterns of symptoms: from asymptomatic to states with few symptoms despite huge metabolic abnormalities whose prognosis is immediately life-threatening. Beyond the inhibition of DNA polymerase gamma using nucleoside analogs, responsible for decreasing mitochondrial DNA in certain targeted organs, it appears that several physiopathologic mechanisms interact to explain this observed toxicity, HIV itself plays a role, and the underlying genetic pool needs to be better identified. Such cases mean that, it is imperative to avoid cumulated toxicities caused by associated treatments. With serious cases, or persistent symptoms despite discontinuing the nucleoside analogs responsible for such toxicity, one must propose vitamins, mitochondrial co-factors, or anti-oxidants. However, the future lies in the use of potent, less toxic nucleoside analogs, and in developing compounds belonging to other classes of antiretrovirals.


Assuntos
Fármacos Anti-HIV/efeitos adversos , Infecções por HIV/complicações , Doenças Mitocondriais/induzido quimicamente , Acidose Láctica/etiologia , Adulto , Fármacos Anti-HIV/farmacologia , Fármacos Anti-HIV/uso terapêutico , Antimetabólitos/efeitos adversos , Antioxidantes/uso terapêutico , Terapia Antirretroviral de Alta Atividade/efeitos adversos , Criança , Pré-Escolar , Fígado Gorduroso/etiologia , Infecções por HIV/tratamento farmacológico , Síndrome de Lipodistrofia Associada ao HIV/induzido quimicamente , Síndrome de Lipodistrofia Associada ao HIV/etiologia , Doenças Hematológicas/etiologia , Humanos , Lactente , Interferon-alfa/uso terapêutico , Nefropatias/etiologia , Lactatos/sangue , Masculino , Mitocôndrias/efeitos dos fármacos , Doenças Mitocondriais/complicações , Doenças Mitocondriais/diagnóstico , Doenças Mitocondriais/tratamento farmacológico , Miosite/etiologia , Nucleosídeos/efeitos adversos , Pancreatite/etiologia , Doenças do Sistema Nervoso Periférico/etiologia
17.
Med Mal Infect ; 35(10): 492-9, 2005 Oct.
Artigo em Francês | MEDLINE | ID: mdl-16316731

RESUMO

BACKGROUND: Rotavirus is the most common cause of severe diarrhea in children. Morbidity and mortality related to rotavirus infection is not well known in temperate countries in general, and in France in particular. OBJECTIVES: The aim of this study was estimate the morbidity, mortality, and cost related to the rotavirus infection in France, in order to assess the potential impact of a vaccination program. METHODS: A birth cohort was followed until 5 years of age using a decision tree model. Rotavirus infection incidence rates were modeled according to age, seasons, and breast-feeding status. RESULTS: Based on estimates from a decision model, we found that in France, rotavirus infection was responsible for 300,000 annual episodes of acute diarrhea, 138,000 visits to general practitioners, 18,000 hospitalizations, and 9 deaths. The annual direct cost related to rotavirus infection care was estimated at 28 million euros. CONCLUSION: This study demonstrates the high morbidity and cost of care associated with rotavirus infection in France. The decision tree model developed in this study could be used in the future to estimate the potential effectiveness, cost and cost-effectiveness of childhood vaccination strategies using new rotavirus vaccines.


Assuntos
Infecções por Rotavirus/epidemiologia , Pré-Escolar , Estudos de Coortes , Custos e Análise de Custo , Árvores de Decisões , Diarreia/economia , Diarreia/epidemiologia , Diarreia/virologia , Medicina de Família e Comunidade/estatística & dados numéricos , França/epidemiologia , Humanos , Lactente , Pacientes Internados/estatística & dados numéricos , Morbidade , Infecções por Rotavirus/economia , Infecções por Rotavirus/mortalidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...